The Future of ANCA-associated Vasculitis

Rheumatic Disease Clinics of North America

Volumn 36, Issue 3, 2010, Pages 609-621

  Holle, Julia U ^a   Wieczorek, Stefan ^b   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

ANCA associated vasculitis; Clinical manifestations; Treatment; Wegener's granulomatosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; AZATHIOPRINE; BELIMUMAB; BORTEZOMIB; CYCLOPHOSPHAMIDE; EPRATUZUMAB; HIGH MOBILITY GROUP B1 PROTEIN; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; METHOTREXATE; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OCRELIZUMAB; OFATUMUMAB; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE INHIBITOR; PROTEINASE INHIBITOR 1; RITUXIMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ANTIGEN EXPRESSION; APOPTOSIS; CIRCULATING ENDOTHELIAL CELL; CLINICAL TRIAL; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; GENETIC ANALYSIS; GRANULOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SMALL VESSEL VASCULITIS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION;

EID: 77955242704     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2010.05.007     Document Type: Review

References (75)

1. Walton E.W. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958, 2:265-270.
2. Fauci A.S., Katz P., Haynes B.F., et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979, 301:235-238.
3. Lüdemann G., Gross W.L. Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol 1987, 69:350-357.
4. Falk R.J., Terrell R.S., Charles L.A., et al. Anti-neutrophil cytoplasmatic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990, 87:4115-4119.
5. Calderwood J.M., Williams J.M., Morgan M.D., et al. ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J Leukoc Biol 2005, 77:33-43.
6. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmatic antibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963.
7. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37(2):187-192.
8. Fries J.F., Hunder G.G., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990, 33:1135-1136.
9. Rasmussen N., Jayne R.W.D., Abramowicz D., et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995, 101(Suppl 1):29-34.
10. Hellmich B., Flossman O., Gross W.L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66:605-617.
11. Mukhtyar C., Guillevin L., Cid M.C., et al. EULAR recommendations for the management of primary small vessel vasculitis. Ann Rheum Dis 2009, 68:310-317.
12. Luqmani R.A., Bacon P.A., Moots R.J., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87:671-681.
13. De Groot K., Gross W.L., Herlyn K., et al. Development and validation of a Disease Extent Index for Wegener's granulomatosis. Clin Nephrol 2001, 55:31-38.
14. Exley A.R., Bacon P.A., Luqmani R.A., et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997, 40:371-380.
15. Eriksson P., Jacobsson L., Lindell A., et al. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009, 265:496-506.
16. Stratta P., Marcuccio C., Campo A., et al. Improvement in relative survival of patients with vasculitis: study of 101 cases compared to the general population. Int J Immunopathol Pharmacol 2008, 21:631-642.
17. Esnault V.L., Testa A., Audrian M., et al. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993, 43:1329-1332.
18. Mahr AD, Edberg J, Stone J, et al. Alpha 1-antitrypsin deficiency and the risk for Wegener's granulomatosis. In: Proceedings of the 14th International Vasculitis and ANCA Workshop [abstract N1]. APMIS 2009;117(Suppl 127):157.
19. Jagiello P., Gencik M., Arning L., et al. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 2004, 114:468-477.
20. Heckmann M., Holle J.U., Arning L., et al. The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterized by tagSNP genotyping. Ann Rheum Dis 2008, 67:972-979.
21. Jagiello P., Aries P., Arning L., et al. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005, 12:4039-4043.
22. Gregersen P.K., Olsson L.M. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009, 27:363-391.
23. Arechiga A.F., Habib T., He Y., et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 2009, 182:3343-3347.
24. Carr E.J., Niederer H.A., Williams J., et al. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med Genet 2009, 10:121.
25. Wieczorek S., Hellmich B., Gross W.L., et al. Associations of the Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of anti-neutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum 2007, 58:329-330.
26. Vaglio A., Martorana D., Maggiore U., et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007, 56:3159-3166.
27. Wieczorek S., Holle J.U., Müller S., et al. A functionally relevant IRF5 haplotype is associated with reduced risk to Wegener's granulomatosis. J Mol Med 2010, 88:413-421.
28. Wieczorek S., Hellmich B., Arning L., et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome. Arthritis Rheum 2008, 58:1839-1848.
29. Xiao H., Schreiber A., Heeringa P., et al. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol 2007, 170:52-64.
30. Kain R., Exner M., Brandes R., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008, 14:1088-1096.
31. Witko-Sarsat V., Lesavre P., Lopez S., et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999, 10:1224-1233.
32. Rarok A.A., Stegeman C.A., Limburg P.C., et al. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002, 13:2232-2238.
33. Matsumoto T., Kaneko T., Wada H., et al. Proteinase 3 expression on neutrophil membranes from patients with infectious disease. Shock 2006, 26(2):128-133.
34. Stegeman C.A., Taervert J.W., Sluiter J.W., et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994, 120:12-17.
35. Belizna C.C., Hamidou M.A., Levesque H., et al. Infection and vasculitis. Rheumatology 2009, 48:475-482.
36. Choi H.K., Lamprecht P., Niles J.L., et al. Subacute bacterial endocarditis with positive cytoplasmatic antineutrophil cytoplasmatic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000, 43:226-231.
37. Gao Y., Zhao M.H. Drug-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 2009, 14:33-41.
38. Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008, 20:35-39.
39. Otsuka S., Kinebuchi A., Tabata H., et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis following propylthiouracil therapy. Br J Dermatol 2000, 142:828-830.
40. Rantapäa-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
41. Csernok E., Ai M., Gross W.L., et al. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via protease-activated receptor-2 pathway. Blood 2006, 107:4440-4448.
42. Hurtado R.R., Jeffs L., Nitschke J., et al. CpG oligodeoxynucleotide stimulates production of antineutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol 2008, 9:34.
43. Kain R., Firmin D.A., Rees A.J. Pathogenesis of small-vessel vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens: new insights from animal models. Curr Opin Rheumatol 2010, 22:15-20.
44. Wiesner O., Litwiller R.D., Hummel A.M., et al. Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments. FEBS Lett 2005, 579:5305-5312.
45. Van der Geld Y.M., Hellmark T., Selga D., et al. Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse PR3 and rat granulocytes. Ann Rheum Dis 2007, 66:1679-1682.
46. Pfister H., Ollert M., Fröhlich L.F., et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004, 104:1411-1418.
47. Fienberg R. The protracted superficial phenomenon in pathergic (Wegener's) granulomatosis. Hum Pathol 1981, 12:458-467.
48. Reinhold-Keller E., de Groot K., Rudert H., et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996, 89:15-23.
49. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43(5):1021-1032.
50. Voswinkel J., Mueller A., Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining antibody production. Ann N Y Acad Sci 2005, 1051:12-19.
51. Voswinkel J., Mueller A., Kraemer J.A., et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006, 65:859-864.
52. Csernok E., Trabandt A., Müller A., et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999, 42:742-750.
53. Cohen Taervert J.W., van der Woude F.J., Fauci A.S., et al. Association between active Wegener's granulomatosis and anticytoplasmatic antibodies. Arch Intern Med 1989, 149:2461-2465.
54. Finkielman J.D., Merkel P.A., Schroeder D., WGET Research Group, et al. Antiproteinase 3 antineutrophil cytoplasmatic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007, 147:611-619.
55. Woywodt A., Streiber F., de Groot K., et al. Circulating endothelial cells as markers for ANCA-associated small vessel vasculitis. Lancet 2003, 361:206-210.
56. Kümpers P., Hellpap J., David S., et al. Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrol Dial Transplant 2009, 24:1845-1850.
57. Erdbrügger U., Grossheim M., Hertel B., et al. Diagnostic role of endothelial microparticles in vasculitis. Rheumatology 2008, 57:1820-1825.
58. Woywodt A., Goldberg C., Kirsch T., et al. Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA-associated vasculitis. Ann Rheum Dis 2006, 65:164-168.
59. Grundmann M., Woywodt A., Kirsch T., et al. Circulating endothelial cells: a marker of vascular damage in patients with preeclampsia. Am J Obstet Gynecol 2008, 198. 317, e1-5.
60. Kniff-Dutmer E.A., Koerts J., Nieuwland R., et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002, 46:1498-1503.
61. Ek M., Popovic K., Harris H.E., et al. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2006, 54:2289-2294.
62. Pagnoux C., Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes?. Curr Opin Rheumatol 2010, 22:21-28.
63. Stone J.H., Merkel P.A., Seo P., et al. Rituximab versus cyclophosphamide for the induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE) [abstract 550]. Arthritis Rheum 2009, 60(Suppl 10):S204.
64. Jones R., Cohen-Tervaert J.W., Hauser T., et al. Randomized trial of rituximab vs. cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS [abstract A24]. APMIS 2009, 117(Suppl 127):78.
65. Levesque M.C. Translational mini-review series on B cell-directed therapies: recent advances in B-cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 2009, 157:198-208.
66. Krumbholz M., Specks U., Wick M., et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005, 25:298-302.
67. Goeb V., Bunch M.H., Vital E.M., et al. Costimulation blockade in rheumatic diseases: where we are?. Curr Opin Rheumatol 2009, 21:244-250.
68. Badger A.M., Griswold D.E., Kapadia R., et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000, 43:175-183.
69. Zarbock A., Lowell C.A., Lay K. Spleen tyrosine kinase Syk is necessary for E-selection-induced alpha(L)beta2 integrin-mediated rolling on intercellular adhesion molecule-1. Immunity 2007, 26:773-783.
70. Hewins P., Williams J.M., Wakelam M.J., et al. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18. J Am Soc Nephrol 2004, 15:796-808.
71. van der Heijden J.W., Oelremans R., Lems W.F., et al. The proteasome inhibitor bortezomib inhibits the release of NFKappaB-inducible cytokines and induces apoptosis of activated T-cells from rheumatoid arthritis patients. Clin Exp Rheumatol 2009, 27:92-98.
72. Neubert K., Meister S., Moser K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
73. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352(4):351-361.
74. Pagnoux C., Mahr A., Hamidou M.A., et al. Azathioprine of methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008, 359:2790-2803.
75. Hiemstra T., Walsh M., de Groot K., et al. Randomized trial of mycophenolate mofetil vs. azathioprine for maintenance therapy in ANCA-associated vasculitides (AAV) [abstract A23]. APMIS 2009, 117(Suppl 127):77.